Showing results (371-380 of 1,842) with videos related to

Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|December 24, 2025
Herpes zoster vaccine uptake following provider prescription among older adults in the United StatesJustin Carrico, Yong Zhu, Lisa Le, et al.
Journal of Managed Care & Specialty Pharmacy|December 24, 2025
Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United StatesNsima Akpan, Bo Zhou, Rafia S Rasu, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Impact of a pharmacy care management service on cardiometabolic medication adherence and resource use for Medicare Advantage beneficiariesShawn Hallinan, Loren Lidsky, Josh Benner, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non-small cell lung cancerXiangzhong Xue, Matthew Loop, Brandon Johnson, et al.
Journal of Managed Care & Specialty Pharmacy|September 26, 2025
Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetesJun Wu, Alexandra Perez, Patrick W Sullivan
Journal of Managed Care & Specialty Pharmacy|September 17, 2025
Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysisPatrick Squires, Erin E Cook, Yan Song, et al.
Journal of Managed Care & Specialty Pharmacy|September 26, 2025
AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphomaBridget Flavin, Denise Wolff, Laura R Bobolts, et al.
Journal of Managed Care & Specialty Pharmacy|September 26, 2025
Examining racial and ethnic differences in health care expenditures among older adults with arthritis in the United StatesSamuel C Ofili, Paroma Arefin, Olajumoke A Olateju, et al.
Journal of Managed Care & Specialty Pharmacy|May 20, 2025
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanomaKirollos S Hanna, Jennell Palaia, Divya Patel, et al.
Pageof 185